Variant-specific SARS-CoV-2 within-host kinetics.
SARS-Cov2
ddPCR
variant of concern
viral dynamics
within-host
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
24
03
2022
received:
11
02
2022
accepted:
31
03
2022
pubmed:
5
4
2022
medline:
16
6
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Since early 2021, SARS-CoV-2 variants of concern (VOCs) have been causing epidemic rebounds in many countries. Their properties are well characterized at the epidemiological level but the potential underlying within-host determinants remain poorly understood. We analyze a longitudinal cohort of 6944 individuals with 14 304 cycle threshold (Ct) values of reverse-transcription quantitative polymerase chain reaction (RT-qPCR) VOC screening tests performed in the general population and hospitals in France between February 6 and August 21, 2021. To convert Ct values into numbers of virus copies, we performed an additional analysis using droplet digital PCR (ddPCR). We find that the number of viral genome copies reaches a higher peak value and has a slower decay rate in infections caused by Alpha variant compared to that caused by historical lineages. Following the evidence that viral genome copies in upper respiratory tract swabs are informative on contagiousness, we show that the kinetics of the Alpha variant translate into significantly higher transmission potentials, especially in older populations. Finally, comparing infections caused by the Alpha and Delta variants, we find no significant difference in the peak viral copy number. These results highlight that some of the differences between variants may be detected in virus load variations.
Identifiants
pubmed: 35373851
doi: 10.1002/jmv.27757
pmc: PMC9088644
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3625-3633Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
BMC Med. 2021 Apr 27;19(1):106
pubmed: 33902581
Trends Microbiol. 2021 Nov;29(11):970-972
pubmed: 34535373
PLoS Comput Biol. 2021 Mar 17;17(3):e1008785
pubmed: 33730053
J Med Virol. 2022 Aug;94(8):3625-3633
pubmed: 35373851
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Open Forum Infect Dis. 2022 Apr 13;9(7):ofac192
pubmed: 35791353
J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):431-43
pubmed: 24961742
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Trends Ecol Evol. 2009 Mar;24(3):127-35
pubmed: 19185386
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17441-6
pubmed: 17954909
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Swiss Med Wkly. 2020 Aug 05;150:w20336
pubmed: 32757177
Elife. 2021 Sep 27;10:
pubmed: 34569939
Int J Infect Dis. 2021 Dec;113:12-14
pubmed: 34601145
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269174
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
CMAJ. 2021 Oct 25;193(42):E1619-E1625
pubmed: 34610919
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Euro Surveill. 2021 Sep;26(37):
pubmed: 34533119
Euro Surveill. 2022 Feb;27(6):
pubmed: 35144725
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Emerg Infect Dis. 2021 May;27(5):1496-1499
pubmed: 33769253
Science. 2021 Feb 5;371(6529):574-575
pubmed: 33542127
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Infect. 2022 Jan;84(1):94-118
pubmed: 34329672
Elife. 2021 Jul 12;10:
pubmed: 34250907